Radiopharmaceuticals and the PET probe in the detection of Ductal Carcinoma in situ of the breast

The use of a hand-held positron emission tomography (PET) probe during breast surgery can potentially reduce the rate of second operations, having a number of implications. The PET probe tested in ductal carcinoma in situ (DCIS) surgery demonstrated to be 96.5% accurate when compared to pathology. T...

Full description

Bibliographic Details
Main Author: Butler-Henderson, Kerryn Ann
Format: Thesis
Language:English
Published: Curtin University 2014
Online Access:http://hdl.handle.net/20.500.11937/2414
_version_ 1848743947879317504
author Butler-Henderson, Kerryn Ann
author_facet Butler-Henderson, Kerryn Ann
author_sort Butler-Henderson, Kerryn Ann
building Curtin Institutional Repository
collection Online Access
description The use of a hand-held positron emission tomography (PET) probe during breast surgery can potentially reduce the rate of second operations, having a number of implications. The PET probe tested in ductal carcinoma in situ (DCIS) surgery demonstrated to be 96.5% accurate when compared to pathology. This research examines the current technology available, the epidemiology of DCIS in Western Australia, testing of the radiopharmaceutical used with the probe and the PET probe itself.
first_indexed 2025-11-14T05:53:40Z
format Thesis
id curtin-20.500.11937-2414
institution Curtin University Malaysia
institution_category Local University
language English
last_indexed 2025-11-14T05:53:40Z
publishDate 2014
publisher Curtin University
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-24142017-02-20T06:38:10Z Radiopharmaceuticals and the PET probe in the detection of Ductal Carcinoma in situ of the breast Butler-Henderson, Kerryn Ann The use of a hand-held positron emission tomography (PET) probe during breast surgery can potentially reduce the rate of second operations, having a number of implications. The PET probe tested in ductal carcinoma in situ (DCIS) surgery demonstrated to be 96.5% accurate when compared to pathology. This research examines the current technology available, the epidemiology of DCIS in Western Australia, testing of the radiopharmaceutical used with the probe and the PET probe itself. 2014 Thesis http://hdl.handle.net/20.500.11937/2414 en Curtin University fulltext
spellingShingle Butler-Henderson, Kerryn Ann
Radiopharmaceuticals and the PET probe in the detection of Ductal Carcinoma in situ of the breast
title Radiopharmaceuticals and the PET probe in the detection of Ductal Carcinoma in situ of the breast
title_full Radiopharmaceuticals and the PET probe in the detection of Ductal Carcinoma in situ of the breast
title_fullStr Radiopharmaceuticals and the PET probe in the detection of Ductal Carcinoma in situ of the breast
title_full_unstemmed Radiopharmaceuticals and the PET probe in the detection of Ductal Carcinoma in situ of the breast
title_short Radiopharmaceuticals and the PET probe in the detection of Ductal Carcinoma in situ of the breast
title_sort radiopharmaceuticals and the pet probe in the detection of ductal carcinoma in situ of the breast
url http://hdl.handle.net/20.500.11937/2414